Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
IBCSG 67-22 PREcoopERA: A Window-of-Opportunity trial of giredestrant +/- triptorelin vs. anastrozole + triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
Operational learnings available2 trial-level findings · Read insights
- The trial randomized 231 patients at 33 centers in six countries between 25 January 2024 and 15 July 2025, exceeding the planned randomization of 220 patients.
- Of 231 randomized patients, 226 initiated window-of-opportunity treatment, 216 had paired biopsies, and 204 met criteria for the primary analysis population.
These findings describe the trial, not the service provider’s performance or responsibility.
POLAR: A phase III open-label, multicenter, randomized trial of adjuvant palbociclib in combination with endocrine therapy versus endocrine therapy alone for patients with hormone receptor positive / HER2-negative resected isolated locoregional recurrence of breast cancer
Sponsor ETOP IBCSG Partners Foundation
- Start (EU)
- Latest update
- Estimated end
"DEMETER": Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients: a multicenter phase II trial
Sponsor Institut Curie
- Start (EU)
- Latest update
- Estimated end
- Not reported
PHASE 2 DOSE-RANGING AND INTERCEPTION STUDY OF LINVOSELTAMAB IN PATIENTS WITH HIGH-RISK MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE OR NON-HIGH-RISK SMOLDERING MULTIPLE MYELOMA
Sponsor Regeneron Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients with Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)
Sponsor Artios Pharma Limited
- Start (EU)
- Latest update
- Estimated end
A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as pre transplant INDUCTION and post transplant consolidation or continuous treatment with CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 cycles) without transplant, all followed by MAINTENANCE with LENALIDOMIDE (R) versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT
Sponsor Universita' Degli Studi Di Torino
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intravenously in Patients with Advanced High-Grade Osteosarcoma
Sponsor Vall D Hebron Institute Of Oncology
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Dana-Farber Cancer Institute?
The 2026-10-09 snapshot links Dana-Farber Cancer Institute to 7 distinct CTIS trials. Recorded services include Laboratory services, Statistical analysis, Clinical monitoring, Data management, among 8 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Dana-Farber Cancer Institute?
The most frequently recorded therapeutic areas are Solid Tumor Oncology. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Dana-Farber Cancer Institute conducted?
The linked trials record locations in 10 countries, including Spain, France, Italy, Hungary, Ireland. These are trial locations, not confirmed office locations or countries where Dana-Farber Cancer Institute delivered services.
What can this page tell me about Dana-Farber Cancer Institute's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Dana-Farber Cancer Institute. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Dana Farber Cancer Institute Inc.
- Dana-Farber Cancer Institute Inc.